InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,222.68
(
0.16%
)
US TECH 100
17,712.40
(
0.17%
)
Dow Jones
39,512.84
(
0.32%
)
Brent Oil
82.89
(
0.61%
)
Bitcoin
62,811.65
(
2.22%
)
Post# of 251799
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

mcbio

Send PM Follow Ignore
Followers 69
Posts 6152
Boards Moderated 0
Alias Born 11/26/2008

mcbio

Re: DewDiligence post# 186822

Friday, 01/30/2015 11:00:18 PM

Friday, January 30, 2015 11:00:18 PM

Post# of 251799
TCON

TRC105, an anti-endoglin antibody that is being developed for the treatment of multiple solid tumor types, and TRC102, a small molecule that is being developed for the treatment of lung cancer and glioblastoma. Both TRC105 and TRC102 are being developed for treatment in combination with currently available therapies.

Isn't it a little bit of a red flag that TRC105 has been in clinical development since the beginning of 2008 (http://www.traconpharma.com/pr_01_9_08.php ) and is only in early Phase 2 trials now? Why such a slow development? Also, several of the trials I've looked at for TRC105 are just single-arm trials. Have they run any controlled trials for the drug in the 7 years that it's been in the clinic?
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up